Pear Therapeutics brings new market opportunity with FDA approval

February 20, 2019 | Case Study

Pear Therapeutics, a digital therapeutics company, launched its first FDA-approved product in late 2018. The therapeutic, called reSET, treats substance abuse disorder (SAD) using cognitive behavioral therapy (CBT) techniques presented in modules. By digitizing the standard treatment of CBT, the value proposition is a more scalable and convenient solution than the standard therapist-moderated version.  The therapeutic is only available by prescription and is prescribed for a 90-day period. The designation of FDA approval was a first for a digital therapeutic and came at the specific request of Pear Therapeutics. When Pear Therapeutics reached out to the FDA in 2015, its request for approval raised questions that ultimately led to the development of the Digital Health Innovation Action Plan and began to shape the digital therapeutics space.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978